Document:

EX-10.1

 Exhibit 10.1 
 December 15, 2014 
 Mr. Richard King 

 

	Re:	Separation Agreement 

 Dear Richard:

 This letter contains the terms of the separation agreement (the “Agreement”) which AcelRx Pharmaceuticals, Inc. (the
“Company”) is offering to you to assist you in your employment transition. 
 1. SEPARATION
DATE. You will remain employed with the Company in your current position of Chief Executive Officer, on the terms and conditions described herein, until the earliest to occur of the following events:
(i) the date that the Company hires a new Chief Executive Officer; or (ii) the Board requests your resignation; or (iii) March 31, 2015. Your final date of employment is referred to herein as your
“Separation Date.” Your separation hereunder shall be deemed a Separation from Service (as those terms are defined in your December 31, 2010 Amended and Restated Offer Letter)(the “Offer Letter”).

 2. TRANSITION PERIOD. From the date of this Agreement through the Separation
Date (the “Transition Period”), you will continue in your capacity as Chief Executive Officer, you will continue to perform your assigned duties to the best of your abilities, and you will continue to abide by all Company policies
and procedures and any agreements between you and the Company. During the Transition Period, you will be paid your current base salary and you will continue to be eligible to participate in the Company’s bonus plan and employee benefit plans
pursuant to the terms of those plans. 
 3. SEVERANCE BENEFITS. Pursuant to the terms
of your Offer Letter, your employment separation shall be deemed a termination without Cause which is not in connection with a Change in Control. Consequently, if you: (i) sign this Agreement; (ii) allow the releases
contained herein to become effective (as required by your Offer Letter); (iii) on or after the Separation Date, you sign and allow to become enforceable the Separation Date Release attached hereto as Exhibit A;
(iv) continue to comply with your obligations under your Proprietary Information Agreement (as defined in your Offer Letter) during the period of time in which you are receiving the Severance Benefits specified herein; and
(v) resign from the Company’s Board effective on such date as requested by the Board; then the Company will provide you with the following severance benefits: 
 (a) Salary Continuation. The Company will pay you an amount equal to twelve (12) months of your current base salary, subject to applicable tax withholdings, paid (except as set forth below)
over the first 12 months following your Separation Date (such 12 month period, the “Severance Period”, and such benefit, the “Salary Continuation”). 

 (b) COBRA Payments. If you timely elect continued coverage under the health care
continuation laws commonly known as COBRA for yourself and your covered dependents, then the Company shall pay, directly to the COBRA carrier as and when due, the COBRA premiums necessary to continue your health insurance coverage in effect for
yourself and your eligible dependents from your termination date until the earliest of (A) the end of the Severance Period, (B) the expiration of your eligibility for the continuation coverage under COBRA, or (C) the date when you
become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A) through (C), the “COBRA Payment
Period”). Notwithstanding the foregoing, if at any time the Company determines that the payment of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or
regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company will
instead pay to you on the first day of each month of the remainder of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings (such amount, the “Special
Severance Payment”), for the remainder of the COBRA Payment Period. If you become eligible for coverage under another employer’s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause,
you must immediately notify the Company of such event, and all payments and obligations under this clause shall cease. 
 (c) Payment Dates. Notwithstanding the payment schedules described above, no payments will be made prior to the 30th day following your Separation Date. On the 30th day following your Separation Date, the Company will pay, in a lump sum, the Severance Benefits that would have
otherwise been paid on or prior to such date under the original schedule but for the delay while waiting for the
30th day in compliance with Section 409A and the
effectiveness of the release, with the balance of the Severance Benefits being paid as originally scheduled. 
 4.
OPTIONS AND RESTRICTED STOCK UNITS (RSUS). Any stock options granted to you shall cease vesting as of the Separation Date. Similarly, any restricted
stock units provided to you shall also cease vesting as of the Separation Date and any restricted stock units which are unvested as of the Separation Date shall terminate and be returned to the applicable plan. Notwithstanding anything to the
contrary in your stock option agreements and the governing stock option plan, if you: (i) sign this Agreement and allow the releases contained herein to become effective; (ii) on or after the Separation Date, you sign and
allow to become enforceable the Separation Date Release attached hereto as Exhibit A; and (iii) prior to the Separation Date, your employment is not terminated for “Cause” (as defined in the Offer Letter) and you do not resign
your employment (except upon the Board’s request); then the Company will extend your exercise period for any options which are vested and exercisable as of the Separation Date until December 31, 2015. You acknowledge that the extension of
the exercise period may change the tax treatment accorded to your options; you are encouraged to seek your own tax advice as to your options; and the Company makes no representation as to tax treatment of your options. Except as expressly modified
in this Section 4 herein, your stock options shall continue to be governed by your stock option agreements and governing stock option plan, and your restricted stock units shall continue to be governed by your restricted stock purchase
agreements. 

 5. UNEMPLOYMENT BENEFITS. You are entitled to
submit a claim for unemployment compensation benefits to the Employment Development Department for the State of California (the “EDD”). Your eligibility to receive unemployment compensation will be determined solely by the EDD. As part of
this Agreement, the Company agrees that it will not characterize your separation as a voluntary departure “without good cause,” or as a discharge in connection with “misconduct,” as those terms are defined in California
Unemployment Insurance Code Section 1256, and will not in any manner challenge or dispute any claim for unemployment compensation benefits that you may bring. 
 6. NO OTHER COMPENSATION OR BENEFITS. You acknowledge that, except as expressly provided in this
Agreement, you have not earned and will not receive from the Company any additional compensation such as base salary, bonus, variable compensation, equity, severance, or benefits on or after the Separation Date, with the exception of any vested
right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested options (if timely exercised by you). By way of example, but not limitation, you represent and warrant that you have not
earned, and are not owed, any commissions, bonus, or incentive compensation that has not already been paid to you. 
 7.
EXPENSE REIMBURSEMENTS. The Company will reimburse you for expenses pursuant to its regular business practice provided you submit your final documented expense reimbursement statement reflecting
all business expenses you incurred through the Separation Date, within seven (7) days of the Separation Date. 
 8.
RETURN OF COMPANY PROPERTY. Within seven (7) days after the Separation Date, you will return to the Company all Company documents (and all copies thereof) and
other Company property which you have in your possession or control, including, but not limited to, Company files, clinical data, research and development information, operational and personnel information, sales and marketing information, customer
lists, prospect information, notes, drawings, records, plans, forecasts, reports, financial data, payroll information, spreadsheets, studies, analyses, proposals, agreements, specifications, code, software, databases, computer-recorded information,
tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones, servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any
proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). You agree that you will make a diligent search to locate any such documents, property and information within the required timeframe.

 9. PROPRIETARY INFORMATION OBLIGATIONS. You acknowledge and
reaffirm your continuing obligations under your Proprietary Information Agreement, a copy of which is attached as Exhibit B and incorporated herein by reference. 
 10. NO DISPARAGEMENT. You agree not to disparage the Company, and the Company’s officers, directors, employees, shareholders and agents, in
any manner likely to be harmful to them or their business, business reputation or personal reputation, and the Company agrees to direct its officers and directors not to disparage you in any manner likely to be harmful to your business, business
reputation or personal reputation; provided that both you and the Company may respond accurately and fully to any question, inquiry or request for information when required by legal process. 

 11. NO ADMISSIONS. The promises and payments in
consideration of this Agreement shall not be construed to be an admission of any liability or obligation by either party to the other party and neither party makes any such admission. 
 12. COOPERATION AND ASSISTANCE. You agree that you will not voluntarily provide assistance, information or advice, directly or
indirectly (including through agents or attorneys), to any person or entity in connection with any claim or cause of action of any kind brought against the Company, nor shall you induce or encourage any person or entity to bring such claims.
However, it will not violate this Agreement if you testify truthfully when required to do so by a valid subpoena or under similar compulsion of law. Further, you agree to voluntarily cooperate with the Company if you have knowledge of facts relevant
to any threatened or pending litigation against the Company by making yourself reasonably available for interviews with the Company or its legal counsel, for preparing for and providing deposition testimony, and for preparing for and providing trial
testimony. Nothing in this Agreement shall affect any rights to indemnity and defense costs that you may have pursuant to your Indemnification Agreement with the Company dated 21 November 2014 (the “Indemnification Agreement”).

 13. RELEASE OF CLAIMS  

(a) General Release. In exchange for the consideration provided to you under this Agreement to which you would not otherwise be
entitled, you hereby generally and completely release the Company and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates,
and assigns (collectively, the “Released Parties”) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to
or on the date you sign this Agreement (collectively, the “Released Claims”). 
 (b) Scope of
Release. The Released Claims include, but are not limited to: (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii) all claims related to your compensation
or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (iii) all claims for breach of
contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all
federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Age Discrimination in
Employment Act of 1967 (as amended) (the “ADEA”), the federal Americans with Disabilities Act of 1990, the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended). 

(c) ADEA Waiver. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the
ADEA, and that the consideration given for the waiver and release in this Section 14 is in addition to anything of value to which you are already entitled. You further acknowledge that you have been advised, as required by the ADEA, that:
(i) your waiver and release do not apply to any rights or claims that may arise after the date that you sign this Agreement; (ii) you should consult with an attorney  

 
prior to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have twenty-one (21) days in which to consider this Agreement (although you may choose
voluntarily to sign it earlier); (iv) you have seven (7) days following the date you sign this Agreement to revoke the Agreement (by providing written notice of your revocation to the Company); and (v) this Agreement will not be
effective until the date upon which the revocation period has expired, which will be the eighth day after the date that this Agreement is signed by you provided that you do not revoke it (the “Effective Date”).  

(d) Waiver of Unknown Claims. In giving the releases set forth in this Agreement, which include claims which may be unknown to you
at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or
her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” You hereby expressly waive and relinquish all rights and benefits under that section and any
law or legal principle of similar effect in any jurisdiction with respect to your release of claims herein, including but not limited to the release of unknown and unsuspected claims. 

(e) Excluded Claims. Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded
Claims”): (i) any rights or claims for indemnification you may have pursuant to the Indemnification Agreement or the charter, bylaws, or operating agreements of the Company, or under applicable law; (ii) any rights which are not
waivable as a matter of law; and (iii) any claims for breach of this Agreement. In addition, nothing in this Agreement prevents you from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity
Commission, the Department of Labor, the California Department of Fair Employment and Housing, or any other government agency, except that you acknowledge and agree that you are hereby waiving your right to any monetary benefits in connection with
any such claim, charge or proceeding. You hereby represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims.

 13. DISPUTE RESOLUTION. To ensure rapid and economical resolution of any disputes regarding this
Agreement, the parties hereby agree that any and all claims, disputes or controversies of any nature whatsoever arising out of, or relating to, this Agreement, or its interpretation, enforcement, breach, performance or execution, your employment
with the Company, or the termination of such employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in San Francisco, CA conducted before a single arbitrator by JAMS, Inc.
(“JAMS”) or its successor, under the then applicable JAMS arbitration rules. The parties each acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any such dispute, claim or demand through a
trial by jury or judge or by administrative proceeding. You will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution
of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any,
awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this
paragraph apply to a dispute, controversy,  

 
or claim sought to be resolved in accordance with these arbitration procedures. Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in
court to prevent irreparable harm pending the conclusion of any arbitration. 
 14. MISCELLANEOUS.
This Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to the subject matter hereof. It is entered into without reliance on any promise or representation, written or
oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter. This Agreement may not be modified or amended except in a writing signed by both you
and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and
assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be
rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of
law principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive
breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures. 

If this Agreement is acceptable to you, please sign and date below and return the fully signed Agreement to me within 21 days of your receipt of this
Agreement. The Company’s offer contained herein will automatically expire if we do not receive the fully signed Agreement from you within this timeframe. 

 Thank you for your efforts on behalf of the Company and I wish you the best in your future endeavors.

  

			
		 	Sincerely,
		
		 	AcelRx Pharmaceuticals, Inc.
		
	By:	 	 /s/ Adrian Adams

		 	Adrian Adams
		 	Chairman of the Board

  

	
	UNDERSTOOD AND AGREED:
	
	 /s/ Richard King

	Richard King
	
	 December 15, 2014

	Date

 EXHIBIT A 

SEPARATION DATE RELEASE 
 In exchange for the consideration provided to me under this Agreement to which I would not otherwise be entitled, I hereby generally and completely release the Company and its current and former
directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all claims,
liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date I sign this Agreement (collectively, the “Released
Claims”). 
 The Released Claims include, but are not limited to: (i) all claims arising out of or in any way
related to my employment with the Company, or the termination of that employment; (ii) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance
pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort
claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation,
attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Age Discrimination in Employment Act of 1967 (as amended) (the “ADEA”), the federal Americans with Disabilities Act
of 1990, the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended). 
 I acknowledge
that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA, and that the consideration given for the waiver and release in this Section 14 is in addition to anything of value to which I am already entitled. I
further acknowledge that I have been advised, as required by the ADEA, that: (i) my waiver and release do not apply to any rights or claims that may arise after the date that I sign this Separation Date Release; (ii) I should consult with
an attorney prior to signing this Separation Date Release (although I may choose voluntarily not to do so); (iii) I have twenty-one (21) days in which to consider this Separation Date Release (although I may choose voluntarily to sign it
earlier); (iv) I have seven (7) days following the date I sign this Separation Date Release to revoke the Separation Date Release (by providing written notice of my revocation to the Company); and (v) this Separation Date Release will
not be effective until the date upon which the revocation period has expired, which will be the eighth day after the date that this Separation Date Release is signed by me provided that I do not revoke it (the “Effective Date”). 

 In giving the releases set forth in this Separation Date Release, which include claims which may be unknown to you at present, I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the
time of executing the release, which if known by him or her must have materially affected his or 

  
 A-1

 
her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction
with respect to my release of claims herein, including but not limited to the release of unknown and unsuspected claims. 

Notwithstanding the foregoing, the following are not included in the Released Claims (the “Excluded Claims”): (i) any rights or
claims for indemnification I may have pursuant to any written indemnification agreement with the Company to which I am a party, the charter, bylaws, or operating agreements of the Company, or under applicable law; (ii) any rights which are not
waivable as a matter of law; and (iii) any claims for breach of this Agreement. In addition, nothing in this Separation Date Release prevents me from filing, cooperating with, or participating in any proceeding before the Equal Employment
Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing, or any other government agency, except that I acknowledge and agree that I am hereby waiving my right to any monetary benefits in connection
with any such claim, charge or proceeding. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included in the Released Claims.

  

	
	UNDERSTOOD AND AGREED:
	
	  

	Richard King
	
	  

	Date

  
 A-2

 EXHIBIT B 

PROPRIETARY INFORMATION AGREEMENT 

  
 A-3

 ACELRX PHARMACEUTICALS, INC. 

CONFIDENTIAL INFORMATION AND 
 INVENTION ASSIGNMENT AGREEMENT 
 As a condition of my becoming employed (or
my employment being continued) by or retained as a consultant (or my consulting relationship being continued) by AcelRx Pharmaceuticals, Inc., a Delaware corporation (“AcelRx”) or any of its current or future subsidiaries,
affiliates, successors or assigns (collectively, the “Company”), and in consideration of my employment or consulting relationship with the Company and my receipt of the compensation now and hereafter paid to me by the Company, I
agree to the following: 
 1. Employment or Consulting Relationship. I understand and acknowledge that this
Agreement does not alter, amend or expand upon any rights I may have to continue in the employ of, or in a consulting relationship with, or the duration of my employment or consulting relationship with, the Company under any existing agreements
between the Company and me or under applicable law. Any employment or consulting relationship between the Company and me, whether commenced prior to or upon the date of this Agreement, shall be referred to herein as the
“Relationship.” 
 2. Duties. I will perform for the Company such duties as may be
designated by the Company from time to time. During the Relationship, I will devote my best efforts to the interests of the Company and will not engage in other employment or in any activities detrimental to the best interests of the Company without
the prior written consent of the Company. 
 3. At-Will Relationship. I understand and acknowledge
that my Relationship with the Company is and shall continue to be at-will, as defined under applicable law, meaning that either I or the Company may terminate the Relationship at any time for any reason or no reason, without further obligation or
liability. 
 4. Confidential Information. 

(a) Company Information. I agree at all times during the term of my Relationship with the Company and thereafter, to hold
in strictest confidence, and not to use, except for the benefit of the Company to the extent necessary to perform my obligations to the Company under the Relationship, or to disclose to any person, firm, corporation or other entity without written
authorization of the Board of Directors of the Company, any Confidential Information of the Company which I obtain or create. I further agree not to make copies of such Confidential Information except as authorized by the Company. I understand that
“Confidential Information” means any Company proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, suppliers, customer lists and customers
(including, but not limited to, customers of the Company on whom I called or with whom I became acquainted during the Relationship), prices and costs, markets, software, developments, inventions, laboratory notebooks, processes, formulas,
technology, 

 
designs, drawings, engineering, hardware configuration information, marketing, licenses, finances, budgets or other business information disclosed to me by the Company either directly or
indirectly in writing, orally or by drawings or observation of parts or equipment or created by me during the period of the Relationship, whether or not during working hours. I understand that Confidential Information includes, but is not limited
to, information pertaining to any aspect of the Company’s business which is either information not known by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company, or is
otherwise proprietary information of the Company or its customers or suppliers, whether of a technical nature or otherwise. I further understand that Confidential Information does not include any of the foregoing items which has become publicly and
widely known and made generally available through no wrongful act of mine or of others who were under confidentiality obligations as to the item or items involved. 
 (b) Prior Obligations. I represent that my performance of all terms of this Agreement as an employee or consultant of the Company has not breached and will not breach any agreement to
keep in confidence proprietary information, knowledge or data acquired by me prior or subsequent to the commencement of my Relationship with the Company, and I will not disclose to the Company or use any inventions, confidential or non-public
proprietary information or material belonging to any current or former client or employer or any other party. I will not induce the Company to use any inventions, confidential or non-public proprietary information, or material belonging to any
current or former client or employer or any other party. I acknowledge and agree that I have listed on Exhibit D all agreements (e.g., non-competition agreements, non-solicitation of customers agreements, non-solicitation of employees
agreements, confidentiality agreements, inventions agreements, etc.) with a current or former employer, or any other person or entity, that may restrict my ability to accept employment with the Company or my ability as an employee or consultant to
recruit or engage customers or service providers on behalf of the Company, or otherwise relate to or restrict my ability to perform my duties as an employee of the Company or any obligation I may have to the Company. 

(c) Third Party Information. I recognize that the Company has received and in the future will receive confidential
or proprietary information from third parties subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree to hold all such confidential or proprietary
information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out my work for the Company consistent with the Company’s agreement with such third party.

 5. Inventions. 
 (a) Inventions Retained and Licensed. I have attached hereto, as Exhibit A, a list describing with particularity all inventions, original works of authorship, developments,
improvements, and trade secrets which were made by me prior to the commencement of the Relationship (collectively referred to as “Prior Inventions”), which belong solely to me or belong to me jointly with another, which relate in
any way to any of the Company’s proposed businesses, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, I represent that there are no such Prior Inventions. If, in

  
 -2-

 
the course of my Relationship with the Company, I incorporate into a Company product, process or machine a Prior Invention owned by me or in which I have an interest, the Company is hereby
granted and shall have a non-exclusive, royalty-free, irrevocable, perpetual, worldwide license (with the right to sublicense) to make, have made, copy, modify, make derivative works of, use, sell and otherwise distribute such Prior Invention as
part of or in connection with such product, process or machine. 
 (b) Assignment of Inventions. I agree
that I will promptly make full written disclosure to AcelRx, will hold in trust for the sole right and benefit of AcelRx, and hereby assign to AcelRx, or its designee, all my right, title and interest throughout the world in and to any and all
inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws, which I may solely or jointly conceive or develop or reduce to
practice, or cause to be conceived or developed or reduced to practice, during the period of my Relationship with the Company (collectively referred to as “Inventions”), except as provided in Section 5(e) below. I further
acknowledge that all Inventions which are made by me (solely or jointly with others) within the scope of and during the period of my Relationship with the Company are “works made for hire” (to the greatest extent permitted by
applicable law) and are compensated by my salary (if I am an employee) or by such amounts paid to me under any applicable consulting agreement or consulting arrangements (if I am a consultant), unless regulated otherwise by the mandatory law of the
state of California. 
 (c) Maintenance of Records. I agree to keep and maintain adequate and
current written records of all Inventions made by me (solely or jointly with others) during the term of my Relationship with the Company. The records may be in the form of notes, sketches, drawings, flow charts, electronic data or recordings,
laboratory notebooks, and any other format. The records will be available to and remain the sole property of the Company at all times. I agree not to remove such records from the Company’s place of business except as expressly permitted by
Company policy which may, from time to time, be revised at the sole election of the Company for the purpose of furthering the Company’s business. I agree to return all such records (including any copies thereof) to AcelRx at the time of
termination of my Relationship with the Company as provided for in Section 6. 
 (d) Patent and
Copyright Rights. I agree to assist AcelRx, or its designee, at its expense, in every proper way to secure AcelRx’s, or its designee’s, rights in the Inventions and any copyrights, patents, trademarks, mask work rights, moral
rights, or other intellectual property rights relating thereto in any and all countries, including the disclosure to AcelRx or its designee of all pertinent information and data with respect thereto, the execution of all applications,
specifications, oaths, assignments, recordations, and all other instruments which AcelRx or its designee shall deem necessary in order to apply for, obtain, maintain and transfer such rights, or if not transferable, waive such rights, and in order
to assign and convey to AcelRx or its designee, and any successors, assigns and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights
relating thereto. I further agree that my obligation to execute or cause to be executed, when it is in my power to do so, any such instrument or papers shall continue after the termination of this Agreement until the expiration of the last such
intellectual property 

  
 -3-

 
right to expire in any country of the world. If AcelRx or its designee is unable because of my mental or physical incapacity or unavailability or for any other reason to secure my signature to
apply for or to pursue any application for any United States or foreign patents, copyright, mask works or other registrations covering Inventions or original works of authorship assigned to AcelRx or its designee as above, then I hereby irrevocably
designate and appoint AcelRx and its duly authorized officers and agents as my agent and attorney in fact, to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the
application for, prosecution, issuance, maintenance or transfer of letters patent, copyright or other registrations thereon with the same legal force and effect as if originally executed by me. I hereby waive and irrevocably quitclaim to AcelRx or
its designee any and all claims, of any nature whatsoever, which I now or hereafter have for infringement of any and all proprietary rights assigned to AcelRx or such designee. 

(e) Exception to Assignments. I understand that the provisions of this Agreement requiring assignment of Inventions
to AcelRx do not apply to any invention which qualifies fully under the provisions of California Labor Code Section 2870 (attached hereto as Exhibit B). I will advise the Company promptly in writing of any inventions that I believe
meet such provisions and are not otherwise disclosed on Exhibit A. 
 6. Company Property;
Returning Company Documents. I acknowledge and agree that I have no expectation of privacy with respect to the Company’s telecommunications, networking or information processing systems (including, without limitation, stored company
files, e-mail messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice. I further agree that any property situated on the Company’s premises and
owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. I agree that, at the time of termination of my Relationship with
the Company, I will deliver to the Company (and will not keep in my possession, recreate or deliver to anyone else) any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches,
laboratory notebooks, materials, flow charts, equipment, other documents or property, or reproductions of any of the aforementioned items developed by me pursuant to the Relationship or otherwise belonging to the Company, its successors or assigns.
In the event of the termination of the Relationship, I agree to sign and deliver the “Termination Certification” attached hereto as Exhibit C; however, my failure to sign and deliver the Termination Certificate shall in
no way diminish my continuing obligations under this Agreement. 
 7. Notification to Other Parties.

 (a) Employees. In the event that I leave the employ of the Company, I hereby consent to notification by
the Company to my new employer about my rights and obligations under this Agreement. 
 (b)
Consultants. I hereby grant consent to notification by the Company to any other parties besides the Company with whom I maintain a consulting relationship, including parties with whom such relationship commences after the effective
date of this Agreement, about my rights and obligations under this Agreement. 

  
 -4-

 8. Solicitation of Employees, Consultants and Other Parties. I agree
that during the term of my Relationship with the Company, and for a period of twelve (12) months immediately following the termination of my Relationship with the Company for any reason, whether with or without cause, I shall not either
directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt to solicit, induce, recruit, encourage or take away employees or consultants
of the Company, either for myself or for any other person or entity. Further, during my Relationship with the Company and at any time following termination of my Relationship with the Company for any reason, with or without cause, I shall not use
any Confidential Information of the Company to attempt to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or
other person either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company. 

9. Representations and Covenants. 
 (a) Facilitation of Agreement. I agree to execute promptly any proper oath or verify any proper document required to carry out the terms of this Agreement upon the Company’s
written request to do so. 
 (b) Conflicts. I represent that my performance of all the terms of this
Agreement does not and will not breach any agreement I have entered into, or will enter into with any third party, including without limitation any agreement to keep in confidence proprietary information acquired by me in confidence or in trust
prior to commencement of my Relationship with the Company. I agree not to enter into any written or oral agreement that conflicts with the provisions of this Agreement. 
 (c) Voluntary Execution. I certify and acknowledge that I have carefully read all of the provisions of this Agreement and that I understand and will fully and faithfully comply with
such provisions. 
 10. General Provisions. 

(a) Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by
the laws of the State of California, without giving effect to the principles of conflict of laws. 
 (b)
Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and merges all prior discussions between us. No modification or amendment to this
Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties. Any subsequent change or changes in my duties, obligations, rights or compensation will not affect the validity or scope of
this Agreement. 

  
 -5-

 (c) Severability. If one or more of the provisions in this Agreement
are deemed void by law, then the remaining provisions will continue in full force and effect. 
 (d)
Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives, and my successors and assigns, and will be for the benefit of the Company, its successors, and its
assigns. 
 (e) Survival. The provisions of this Agreement shall survive the termination of the
Relationship and the assignment of this Agreement by the Company to any successor in interest or other assignee. 

(f) Remedies. I acknowledge and agree that violation of this Agreement by me may cause the Company irreparable harm,
and therefore agree that the Company will be entitled to seek extraordinary relief in court, including but not limited to temporary restraining orders, preliminary injunctions and permanent injunctions without the necessity of posting a bond or
other security and in addition to and without prejudice to any other rights or remedies that the Company may have for a breach of this Agreement. 
 (g) ADVICE OF COUNSEL. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL
OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF. 
 [Signature Page Follows] 

  
 -6-

 The parties have executed this Agreement on the respective dates set forth below:

  

									
	COMPANY:	  		  	EMPLOYEE:
			
	ACELRX PHARMACEUTICALS, INC.	  		  	Richard King, an Individual:
					
	By:	  	 /s/ Thomas A. Schreck
	  		  		  	
				
	Name:	  	 Thomas A. Schreck
	  		  	 /s/ Richard King

		  		  		  	Signature
					
	Title:	  	 Chairman
	  		  		  	
					
	Date:	  	 March 10, 2010
	  		  	Date:	  	 3/10/2010

					
	Address:	  	      
	  		  	Address:	  	      

					
		  	      
	  		  		  	      

 SIGNATURE PAGE TO CONFIDENTIAL INFORMATION AND 

INVENTION ASSIGNMENT AGREEMENT OF 
 ACELRX PHARMACEUTICALS, INC. 

 EXHIBIT A 
 LIST OF PRIOR INVENTIONS 
 AND ORIGINAL WORKS OF AUTHORSHIP

 EXCLUDED UNDER SECTION 5 
  

					
	 Title
	  	 Date
	  	 Identifying Number

or Brief Description

		  		  	
		  		  	
		  		  	
		  		  	
		  		  	
		  		  	
		  		  	
		  		  	
		  		  	
		  		  	

  

			
	    No inventions or improvements
	
	    Additional Sheets Attached

			
		
	Signature of Employee/Consultant:	 	  

			
		
	Print Name of Employee/Consultant:	 	  

			
		
	Date:	 	  

 EXHIBIT B 
 Section 2870 of the California Labor Code is as follows: 
 (a) Any provision
in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time
without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: 
 (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or

 (2) Result from any work performed by the employee for the employer. 

(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from
being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable. 

 EXHIBIT C 
 TERMINATION CERTIFICATION 
 This is to certify that I do not have in my
possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, flow charts, materials, equipment, other documents or
property, or copies or reproductions of any aforementioned items belonging to AcelRx Pharmaceuticals, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”). 

I further certify that I have complied with all the terms of the Company’s Confidential Information and Invention Assignment
Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined therein), conceived or made by me (solely or jointly with others) covered by that agreement. 

I further agree that, in compliance with the Confidential Information and Invention Assignment Agreement, I will preserve as confidential
all trade secrets, confidential knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship,
customer lists, business plans, financial information or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees. 

I further agree that for twelve (12) months from the date of this Certificate, I shall not either directly or indirectly solicit,
induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt to solicit, induce, recruit, encourage or take away employees or consultants of the Company, either for
myself or for any other person or entity. Further, I shall not at any time use any Confidential Information of the Company to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to
solicit or influence or attempt to influence any client, customer or other person either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution or other entity in competition
with the business of the Company. 
  

									
	Date:	 	  
	 		 		 	  

		 		 		 		 	(Employee’s Signature)
					
		 		 		 		 	  

		 		 		 		 	(Type/Print Employee’s Name)

 EXHIBIT D 
 LIST OF PRIOR AGREEMENTS 
 EXCLUDED UNDER SECTION 4(b) 

 

			
	    No prior agreements
	
	    Additional Sheets Attached

			
		
	Signature of Employee/Consultant:	 	  

			
		
	Print Name of Employee/Consultant:	 	  

			
		
	Date:Exhibit 10.3

 

BINDING LETTER OF INTENT

 

This Binding
Letter of Intent (this “LOI”) is entered into by and between FREEBUTTON, INC., a Nevada corporation (the “Company”),
and A1 Vapors Inc., a Florida corporation (“A1”).

 

BACKGROUND AND PURPOSE

 

		A.	The Company is a fully reporting publicly traded company with the ticker symbol “FBTN” on the United States over-the-counter
(OTCQB) securities market.

 

		B.	The Company wishes to acquire A1 through a reverse acquisition and believes A1 to have a valuable product and intellectual
property rights related to the electronic vapor cigarette industry. A1 aims at aiding smokers in getting
rid of the harmful cigarette habit by providing them with a revolutionary alternative. A1 Vapors is helping the world transform
the bothersome smoking scene into one that is generally cleaner, safer, less expensive and more enjoyable for smokers and non smokers
alike. In comparison to what is currently on the market, A1 Vapors has surpassed its competition by continuously striving to provide
high quality products at the most affordable rate. A1 Vapors offers a variety of options to choose from to appeal to all smokers
including a diverse selection of devices and flavors. A1 set out to create a company that would offer high quality electronic cigarettes
with many styles to suit all type of smokers. 

 

		C.	The Company and A1 wish to enter into a voluntary share exchange (the “Exchange”) transaction whereby
the Company would acquire all of the issued and outstanding units of A1 in exchange for the issuance to the members of A1 of approximately
21,000,000 shares of common stock of the Company.

 

		D.	The parties wish to enter into this LOI which states that the closing of the Exchange will occur upon completion of the conditions
as set forth herein and in a formal, definitive agreement.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the
mutual agreements and representations contained herein, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the parties agree as follows:

 

1.This LOI constitutes a binding agreement
with regard to the various matters set forth herein and shall become effective on execution of this LOI.

 

2.The Company and A1 agree that they
will enter into a mutually agreed upon definitive agreement containing substantially the same terms and provisions as set forth
in Paragraphs 3-10 of this LOI within thirty (30) days from the date of execution of this LOI (the “Definitive Agreement”).

 

3.Upon the satisfaction of the conditions
set forth herein and in the Definitive Agreement, the Company will acquire all of the issued and outstanding units of A1 in exchange
for the issuance to the members of A1 of 21,000,000 shares of common stock of the Company. At the Closing, A1 shall become wholly-owned
by the Company.

 

    	1

    	 

    

 

4.The closing of the Exchange (the
“Closing”) shall occur on or before thirty (30) days from the date on which A1 completes the audit of
its financial statements as required to be filed by the Company upon the Closing in accordance with the Securities Exchange Act
of 1934, as amended (the “Exchange Act”) and approval by its shareholders of the Definitive Agreement.
Immediately prior to the Closing, the Company will have 33,844,000 shares of common stock, on a fully diluted basis, issued and
outstanding. At the Closing, after giving effect to the Exchange, the capitalization of the Company will be as set forth on Exhibit
A.

 

5.After the Closing, the Company will
be managed by A1’s current management and board of directors. The existing board of directors and officers of the Company
will resign effective as of the Closing and be replaced by officers and directors to be designated by A1. For the avoidance of
doubt, these board of directors will include Bruce Storrs and Andy Diaz and the officers will include Bruce Storrs and Andy Diaz
as well as any other officers and directors designated by A1.

6.At the Closing, the Company will
have no more than approximately $25,000.00 in actual or contingent liabilities outstanding and no undisclosed liabilities, commitments
or other obligations of any kind other than the Company’s obligations to A1 pursuant to this LOI.

 

7.A1 represents that the board of directors
of A1 has approved this LOI and the transactions contemplated hereunder.

 

8.The parties intend for the post-Closing
capitalization table of the Company to be substantially as attached hereto as Exhibit A. Any update to Exhibit A between
now and the execution of the definitive agreement will have no effect on total number of shares (21,000,000) issued by Company
to A1.

 

9.In the Definitive Agreement, A1 will grant to the Company a non-exclusive license (conditioned on Closing) to use the name
“A1 Vapors” or any variation thereof not currently used by A1 and, upon the Closing, the Company may undertake to
change its name to “A1 Vapors, Inc.” or a mutually agreed upon name not used by A1. A1 further agrees to provide consents,
as may be required by the Company to make filings for the use of such name; provided, however, that in no event
shall A be precluded from continuing to use any names currently used by A1. Prior to the Closing, neither the Company nor its
representatives shall make any representations regarding the business or affairs of A1 without the prior written consent of A1.

 

10.The Definitive Agreement shall
contain customary representation and warranties, covenants and indemnification provisions as shall be mutually agreed upon by
A1 and the Company.

 

11.In consideration of the time and effort the Company will incur to pursue this transaction, A1 agrees
that, from the date of execution of this LOI (or, if sooner, until such time as this LOI is terminated) until the Closing, neither
A1 nor any person or entity acting on its behalf will in any way directly or indirectly (i) solicit, initiate, encourage or facilitate
any offer to directly or indirectly purchase A1 or any of its material assets or equity, (ii) enter into any discussions, negotiations
or agreements with any person or entity which provide for such purchase, or (iii) provide to any persons other than its members
or the Company or its representatives any information or data related to such purchase or afford access to the properties, books
or records of A1 to any such persons. If A1, or its representatives receive any inquiry or proposal offering to purchase A1 or
any part of its assets or equity, A1 will promptly notify the Company. No party hereto will make any disclosure or public announcements
of the proposed transactions, the LOI or the terms thereof without the prior consent of the other party, which shall not be unreasonably
withheld, or except, and only to the extent, as required by the applicable rules and regulations of the Securities and Exchange
Commission. The Company agrees to provide to A1 such current information regarding the Company as A1 may reasonably request to
include in any disclosure statement to be provided to A1 members and note holders in connection with soliciting the vote of A1
members and note holders for approval of the Plan of Reorganization and the transactions contemplated thereby.

 

    	2

    	 

    

 

12.Prior to the Closing, the Company
and its representatives shall maintain the confidentiality of all confidential information that is provided to the Company by A1
or its representatives except to the extent such disclosure is required by law. Each party agrees and acknowledges that such party
and its directors, officers, employees, agents and representatives will disclose business information and information about the
proposed transaction in the course of securing financings for the Company and A1 and that the parties and their representatives
may be required to disclose that information under the continuous disclosure requirements of the Exchange Act; provided,
however, that prior to the Closing, the disclosure of any non-public confidential information of A1 may be made by the Company
only with prior approval of A1 and subject to obtaining an appropriate confidentiality agreement from the proposed recipient of
such information.

 

13.This LOI shall be construed in accordance
with, and governed by, the laws of the State of Nevada, and each party separately and unconditionally subjects to the jurisdiction
of any court of competent authority in the State of Nevada, and the rules and regulations thereof, for all purposes related to
this agreement and/or their respective performance hereunder.

 

14.The parties shall prepare, execute
and file any and all documents necessary to comply with all applicable federal and state securities laws, rules and regulations
in any jurisdiction where they are required to do so.

 

15.If any term or provision hereof shall
be held illegal or invalid, this LOI shall be construed and enforced as if such illegal or invalid term or provision had not been
contained herein.

 

16.This LOI may be executed in counterparts,
by original or facsimile signature, with the same effect as if the signatures to each such counterpart were upon a single instrument;
and each counterpart shall be enforceable against the party actually executing such counterpart. All counterparts shall be deemed
an original copy.

 

17.The delay or failure of a party to
enforce at any time any provision of this LOI shall in no way be considered a waiver of any such provision, or any other provision
of this LOI. No waiver of, delay or failure to enforce any provision of this LOI shall in any way be considered a continuing waiver
or be construed as a subsequent waiver of any such provision, or any other provision of this LOI.

 

18.This LOI may be terminated prior
to entering into the Definitive Agreement (i) by mutual written agreement of the parties, (ii) by either party if the Definitive
Agreement has not been entered into by May 31, 2014 through no fault of terminating party, or (iii) by either party in the event
of a material breach of this LOI by the other party, including failure by the Company to promptly fund the LOI Advance after execution
of this LOI

 

 

 

DATED EFFECTIVE: 4/11/14

	 	 	 	 
	 	FREE BUTTON, INC.	 
	 	 	 	 
	 	By:	/s/ James
    Lynch	 
	 	Name:	James Lynch	 
	 	Title: 	Chief Executive Officer	 
	 	 	 	 
	 	A1 VAPORS, INC.	 
	 	 	 	 
	 	By:	/s/ Bruce Storrs	 
	 	Name:	Bruce Storrs	 
	 	Title:	Co-Owner	 

 

 

 

    	3

    	 

    

 

Exhibit A

 

Capitalization Table

 

	 	 	Pre Transaction	 	 	% Ownership	 	 	Post Transaction	 	 	% Ownership	 
	Current Shareholders	 	 	33,844,000.00	 	 	 	100.0	%	 	 	12,844,000.00	 	 	 	38.0	%
	Al Shareholders	 	 	–	 	 	 	0.0	%	 	 	21,000,000.00	 	 	 	62.0	%
	Total	 	 	33,844,000.00	 	 	 	100.0	%	 	 	33,844,000.00	 	 	 	100.0	%

 

 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]